Botulinum Toxin Injection : Treatment for Spasmodic Dysphonia

Abstract

In this proceeding, we report the cases of 487 patients with spasmodic dysphonia (SD) who were injected with botulinum toxin (BT) into their laryngeal muscles (December 2006-January 2014 at Kumada Clinic). The sex ratio was 117:370 (M:F). The type ratio was 459:26:2 (adductor: abductor: “unusual”). This was based on our original classification of SD into three types, with the “unusual type” being defined as that which involves laryngeal muscles other than the TA or PCA, or involves more than two kinds of laryngeal muscles. Recently, we applied BT injections with a low dose-short interval (LDSI) (shorter than eight weeks) for SD patients who wanted to avoid the breathy hoarseness which is usually found for about two weeks after injections. Among 30 cases injected in January 2013, we applied LDSI for 10 cases throughout the following 12 months.